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OBJECTIVE: The aim of this study was to determine the
pretest probability of organic GI disease and the accuracy of
diagnostic tests for organic GI disease in patients who meet
symptom-based criteria for irritable bowel syndrome (IBS).
METHODS: After a comprehensive literature search for stud-
ies examining the accuracy of diagnostic tests for organic GI
disease among patients who meet symptom-based criteria
for IBS, two independent observers qualitatively assessed
the methodology of selected studies and extracted data. Data
on the pretest probability of organic GI disease in this
population and the accuracy of currently recommended di-
agnostic tests were converted to descriptive tables.
RESULTS: Among patients meeting symptom-based criteria
for IBS, the pretest probability of inflammatory bowel dis-
ease, colorectal cancer, or infectious diarrhea is less than
1%. Currently recommended diagnostic tests rarely identify
organic GI disease in patients fulfilling symptom-based cri-
teria for IBS. However, the pretest probability of celiac
disease in patients meeting symptom-based criteria for IBS
was 10 times higher than the prevalence of celiac disease in
the general population.
CONCLUSIONS: There is insufficient evidence to recommend
the routine performance of a standardized battery of diag-
nostic tests in patients who meet symptom-based criteria for
IBS. Based upon the increased pretest probability of celiac
disease, routine performance of serological tests for celiac
disease may be useful in this patient population, though
additional study is needed in this area. (Am J Gastroenterol
2002;97:2812–2819. © 2002 by Am. Coll. of Gastroenter-
ology)
INTRODUCTION
Irritable bowel syndrome (IBS) is a common chronic GI
condition characterized by abdominal pain, bloating, and
disturbed defecation. It is considered one of a group of
functional GI disorders in which altered motility, abnormal
visceral sensation, and psychosocial factors interplay to
cause symptoms. The prevalence of IBS is estimated to be
between 14% and 24% in women and 5–19% in men in the
United States and Britain (1). IBS is responsible for 2.4–3.5
million physician visits per year (2). Recent estimates of the
total direct costs of IBS were $1.6 billion in 1998 (3, 4).
These data confirm that the management of IBS is a signif-
icant public health issue.
The symptoms of IBS are difficult to quantify. There is no
reliable biological marker for the condition, requiring the
use of symptom-based criteria for the diagnosis. Multiple
symptom-based criteria (Table 1) have been developed,
including the Manning, Rome I, and Rome II criteria (5–7).
In particular, the Rome criteria, developed by multinational
working groups, provide a uniform framework for the se-
lection of patients in diagnostic and therapeutic trials of IBS.
Of the commonly used symptom-based criteria for the di-
agnosis of IBS, the Manning criteria have been the most
extensively studied. The positive predictive value of the
Manning criteria for the diagnosis of IBS has ranged be-
tween 65–75%, depending upon the number of symptoms
present and the number of symptoms included for analysis
(in the original Manning study, four of six criteria reached
statistical significance as predictors of IBS, whereas two
others approached statistical significance) (5).
In an attempt to build upon the strengths, while limiting
the weaknesses of the Manning criteria, the Rome I criteria
were developed largely through expert consensus. The
Rome I criteria have been less extensively studied than the
Manning criteria. In one trial that evaluated the diagnostic
accuracy of the Rome I criteria in the absence of “red flag”
symptoms, the sensitivity was 65%, specificity 100%, and
positive predictive value 98% in distinguishing between IBS
and organic disease (8). The Rome II criteria have not been
formally validated but have been compared with the Man-
ning and Rome I criteria in a number of studies. These
studies have reported reasonably good agreement between
the different criteria with  values of about 0.70 (9–11). It
appears, however, that the Rome II criteria may be less
sensitive than the Manning or Rome I criteria (12).
The Rome committee and many IBS authorities recom-
mend that several diagnostic tests be performed as part of
the evaluation of patients with suspected IBS (13, 14). The
most recent American Gastroenterological Association Po-
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sition Statement on IBS recommends the performance of a
complete blood count (CBC), erythrocyte sedimentation
rate (ESR), serum chemistries, and stool examination for
ova and parasites (O&P), and occult blood (FOBT). Colonic
visualization with flexible sigmoidoscopy, barium enema, or
colonoscopy (if the patient is older than 50 yr of age) is also
recommended (15). These evaluations are intended to rule
out inflammatory bowel disease (IBD), colorectal cancer,
and infectious diarrhea. Other experts also recommend the
use of hydrogen breath tests and thyroid function testing
(16, 17) to rule out lactose malabsorption and thyroid dys-
function, respectively. The degree to which these additional
tests add to the diagnostic certainty of IBS, as established by
validated symptom-based criteria such as the Manning or
Rome criteria, is unknown. In other words, does the evi-
dence support the routine application of additional diagnos-
tic testing in patients who meet the Manning, Rome, or other
symptom-based criteria for IBS?
Clinicians should consider several issues when deciding
if a diagnostic test is needed, but two issues deserve partic-
ular attention. First, they should consider the pretest prob-
ability of the disorder based upon the known prevalence of
the disorder in patients with specific symptoms. If the pre-
test probability of a disorder is miniscule, then further di-
agnostic tests may not be necessary (18). Second, clinicians
should consider the accuracy (e.g., sensitivity, specificity,
positive and negative predictive value) of the diagnostic test
if the pretest probability of a disorder is high enough to
warrant investigation. Therefore, a systematic review of the
literature was undertaken to quantify the prevalence of or-
ganic GI disease and to determine the accuracy of the most
commonly employed tests for the diagnosis of organic GI




A search of the online bibliographic databases MEDLINE
and EMBASE was performed to identify all relevant articles
published between 1980 and 2001. The search terms “co-
lonic diseases, functional [diagnosis]” or “irritable, func-
tional, or spastic” adjacent to “bowel or colon” were used.
The search was further supplemented by the addition of
other descriptive key words such as “blood,” “parasite,”
“stool analysis,” “radiography,” “hydrogen breath testing,”
“flexible sigmoidoscopy or colonoscopy or barium enema.”
An expert medical librarian was used to maximize search
techniques and retrieval of targeted information. The bibli-
ographies from all potentially relevant articles were manu-
ally searched. Additionally, abstracts from the annual sci-
entific meetings of the American Gastroenterological
Association (Digestive Disease Week) and the American
College of Gastroenterology (1998–2001) were reviewed.
Study Selection Criteria
Criteria for properly designed studies of diagnostic tests
have been defined (19). These criteria include: 1) indepen-
dent, blind comparison with a reference, or “gold” standard
of diagnosis; 2) evaluation within an appropriate spectrum
of patients where the diagnostic test is likely to be used; and
Table 1. Symptom-Based Criteria for the Diagnosis of IBS




At least 12 wk of continuous or recurrent symptoms
of the following:
At least 12 wk, which need not be consecutive, in
the preceding 12 mo of abdominal discomfort or
pain that has two of the three features:
Looser stools with
the onset of pain
Abdominal pain or discomfort: Relieved with defecation and/or
1) relieved with defecation, or
2) associated with a change in frequency of stool,
or
3) associated with a change in consistency of
stool
More frequent stools
with the onset of
pain
Two or more of the following, at least on one
fourth of occasions or days:
Onset associated with a change in frequency of
stool and/or
1) altered stool frequency, or
2) altered stool form, or
3) altered stool passage, or
4) passage of mucous, or
5) bloating or feeling of abdominal distention
Abdominal distension Onset associated with a change in form
(appearance) of stool
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3) application of the reference standard regardless of the
diagnostic test result (i.e., elimination of verification bias).
To determine the accuracy of diagnostic evaluations in
IBS patients, study selection criteria were: 1) use of a cohort
of IBS patients explicitly diagnosed via symptom-based
criteria (Manning, Rome I, Rome II, or International Con-
gress of Gastroenterology criteria) (20); 2) performance of a
commonly applied diagnostic test with a blinded compari-
son with an appropriate gold standard diagnostic test for
organic GI disease; and/or 3) quantification of the results as
either normal or abnormal in which an additional or alter-
native diagnosis of organic disease was made, based upon
the test result. In all of the studies that fulfilled inclusion
criteria, the diagnosis of IBS was made solely based upon
fulfillment of symptom-based criteria and a priori to the
application of any of the diagnostic tests being evaluated.
Potentially relevant articles were reviewed in an indepen-
dent, unblinded fashion by two authors (B.D.C., P.S.S.) to
determine if they met the validity criteria specified above.
Reviewers rated each article as being eligible, not eligible,
or as having insufficient information to make a judgment as
to eligibility. Any disagreement among reviewers was re-
solved by consensus.
Qualitative Assessment of Study Methodology
Previous reviews have established methodological criteria
by which to determine the quality and validity of trials about
diagnosis (21). The quality of each study selected for this
systematic review was determined by assessing the follow-
ing study characteristics: 1) study population; 2) verifica-
tion; 3) interpretation of test results; 4) patient selection; 5)
data collection; 6) details of test; 7) details of reference test;
and 8) details of population (Table 2). The total score ranged
from 0 to 8. Studies were classified as low quality if they
scored in the lowest tertile or as medium-high quality if they
scored in the middle-to-high tertile, as described in previous
reports (21).
Data Extraction and Statistical Analysis
Eligible articles were reviewed in a blinded fashion by two
different investigators (B.D.C., P.S.S.), and the results of the
primary research studies were abstracted onto specially de-
signed data extraction forms. Data were extracted about: 1)
population, including the proportion of female patients; 2)
symptom-based criteria used (Manning, Rome I/II, Interna-
tional Congress of Gastroenterology); 3) intervention (diag-
nostic evaluation performed and gold standard comparison);
and 4) outcome (prevalence of confirmed organic GI dis-
ease, resulting in an alternative diagnosis to explain IBS
symptoms, and data on the diagnostic accuracy of tests). The
frequency of agreement between reviewers was greater than
95%, and disagreement was resolved through discussion.
To determine the pretest probability of organic GI disease
in patients meeting symptom-based criteria for IBS, the
prevalence of organic GI disease was extracted from study
results and subsequently compared with the background
prevalence based upon general population estimates. The
sensitivity and specificity of each diagnostic test to accu-
rately rule in or rule out a specific organic GI disease among
this unique patient population was calculated when adequate
data were provided to allow this calculation. Because of the
wide variation of study methodology, study results were too
diverse to combine in a true meta-analysis (22). Therefore,
data are simply presented in tabular form.
RESULTS
Characteristics of Selected Studies
A total of 154 potentially relevant references were identified
through the MEDLINE search, EMBASE search, citation
search, and manual searches of abstracts from gastroenter-
ology meetings. Reviews of the titles and abstracts followed
by review of the full manuscripts of potentially relevant
articles identified six published manuscripts (23–28) that
met inclusion criteria. Selected characteristics and qualita-
tive scores of the studies are included in Table 3. Two of the
six studies (25, 27) scored in the highest tertile for meth-
odological quality, and the remaining four studies scored in
the median tertile for methodological quality.














23 1 0 0 1 1 1 0 1
24 1 0 0 1 1 1 0 1
25 1 0 1 1 1 1 0 1
26 1 0 0 1 1 1 0 1
27 0 1 0 1 1 1 1 1
28 1 0 0 1 1 0 1 1
Population: 1  clinical; 0  case-control.
Verification: 1  comparison of diagnostic test to “gold” standard or reference test; 0  no comparison of diagnostic test to reference test.
Interpretation of test: 1  blinded interpretation; 0  nonblinded interpretation.
Patient selection: 1  consecutive; 0  nonconsecutive.
Data collection: 1  prospective; 0  nonprospective.
Details of test: 1  sufficient details of diagnostic test applied; 0  insufficient details of diagnostic test applied.
Details of reference test: 1  sufficient details of reference test used; 0  insufficient details of reference test used.
Details of population: 1  sufficient details regarding study and control populations; 0  insufficient details regarding study and control population.
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Pretest Probability of Organic GI Disease
The pretest probability of various organic GI disease states
in patients meeting symptom-based criteria for IBS is pre-
sented in Table 4. These data were extracted from the
selected published manuscripts that fulfilled study selection
criteria (23–28). For comparison purposes, prevalence rates
of these organic GI diseases in the general population are
also included. The pretest probability of IBD, colon cancer,
lactose malabsorption, and thyroid dysfunction in patients
with suspected IBS was similar to the prevalence of these
disorders in the general population. However, the pretest
probability of celiac disease was 10 times greater in patients
with suspected IBS compared with the estimated prevalence
of celiac disease in the general population.
Colonic Evaluation for IBD, Other Forms of Colitis,
and Colorectal Cancer
Several studies (23–26) have systematically evaluated the
structure of the colon with a variety of testing methods to
identify IBD, colitis, or colorectal cancer among patients
with symptoms of IBS. Hamm et al. (23) examined the use
of flexible sigmoidoscopy, colonoscopy, or barium enema in
patients with suspected IBS fulfilling the Rome I criteria. It
is not clear how many subjects underwent each individual
examination. Among 306 patients studied, four were given
alternative diagnoses (three IBD, one colonic obstruction),
which may have been responsible for their IBS symptoms.
Tolliver et al. performed a similar analysis in 196 subjects
with suspected IBS (24). Like the study by Hamm et al.
(23), the percentage of the cohort that underwent each
examination is unclear. Forty-two colonic structural abnor-
malities were found in 34 subjects. Of these 42 abnormal-
ities, two patients were found to have organic GI diseases
(one IBD, one cancer) that could have been potential causes
of IBS symptoms. The remainder of the abnormalities con-
sisted of benign polyps, diverticulosis, hemorrhoids, lipo-
mata, and melanosis coli.
MacIntosh et al. evaluated flexible sigmoidoscopy in
patients with suspected IBS and in non-IBS controls (25).
Among the IBS cohort, 89% fulfilled the Manning criteria,
and 84% fulfilled the Rome I criteria, whereas 15% of the
controls fulfilled the Manning criteria, and only 5% fulfilled
the Rome I criteria. No patients with suspected IBS were
given alternative diagnoses to explain their GI symptoms
based upon flexible sigmoidoscopy in this trial. Francis et al.
performed colonic examination with flexible sigmoidos-
copy, barium enema, or colonoscopy in 125 patients who
fulfilled the Rome I criteria for IBS (26). Except for inci-
dental diverticular disease, no organic GI disorders were
identified through the performance of these tests, and no
patients were given alternative diagnoses to explain their GI
symptoms as a result of these examinations.
Only one study meeting inclusion criteria evaluated the
Table 3. Summary of Studies Selected













FS, BE, colonoscopy 23 N/A 306 0 45 72 1.31 5/8
24 N/A 196 0 44 81 1.02 5/8
25 N/A 89 59 44 82 0 6/8
26 N/A 125 0 39 80 0 5/8
Rectal biopsy 25 N/A 89 59 44 82 0 6/8
CBC 24 N/A 196 0 44 81 0 5/8
27 N/A 300 300 56 71 0.33 6/8
Chemistries 24 N/A 196 0 44 81 1.02 5/8
27 N/A 300 300 56 71 1.33 6/8
AGA/EmA 27 Duodenal biopsy 300 300 56 71 4.67 6/8
FOBT 24 N/A 183 0 44 81 0 5/8
TSH 23 N/A 1209 0 45 72 6 5/8
24 N/A 171 0 44 81 0.58 5/8
O&P 23 N/A 1154 0 45 72 1.65 5/8
24 N/A 170 0 44 81 0 5/8
Hydrogen breath test 23 N/A 1122 0 45 72 22.8 5/8
24 N/A 186 0 44 81 25.8 5/8
28 N/A 202 0 42 77 78 5/8
Abdominal ultrasound 26 N/A 125 0 39 80 0 5/8
AGA  anti-gliadin antibody; BE  barium enema; EmA  flexible endomysial antibody; FS  flexible sigmoidoscopy; N/A  not applicable.
Table 4. Pretest Probability of Organic GI Disease in Patients









Colorectal cancer 0–0.51 4–6*
Celiac disease 4.67 0.25–0.5†
Gastrointestinal infection 0–1.7 N/A‡
Thyroid dysfunction 6 5–9§
Lactose malabsorption 22–26 25¶
* Reference 4.
† Reference 34.
‡ Reference 4 (unable to quantify point prevalence, but estimates approach annual
incidence of 10–15% of U.S. population).
§ Reference 29.
¶ Reference 30.
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use of rectal biopsies as part of the evaluation of suspected
IBS (25). No patients from among a group of 89 patients
with suspected IBS or 59 non-IBS controls had rectal biopsy
findings that resulted in an alternative or additional diagno-
sis of organic GI disease.
Laboratory Evaluations (CBC, Chemistries, ESR/CRP,
FOBT, Antigliadin/Endomysial Antibodies) for
Identification of IBD, Other Colitides, Colorectal
Cancer, or Celiac Disease
Several reports (24, 27) have examined the use of com-
monly recommended laboratory tests such as CBC, serum
chemistries, and FOBT as part of the diagnostic evaluation
of suspected IBS. In the trial by Tolliver et al., CBC and
serum chemistries were performed in 196 patients with
suspected IBS (24). In no patient did the CBC result in an
alternative diagnosis of organic GI disease. Serum chemis-
tries were abnormal in two patients (1.0%). Both subjects
had abnormal liver-associated enzymes. The etiology of
these abnormalities is not revealed in the article, so it is
unclear whether or not they represented an alternative di-
agnosis of organic GI disease (responsible for the patients’
IBS symptoms), or if they were indicative of a second
disorder in addition to IBS.
Sanders et al. evaluated the use of CBC and serum chem-
istries in 300 patients who fulfilled the Rome II criteria for
IBS (27). They identified five patients (1.67%) who had
organic GI disease. One patient was anemic and later found
to have celiac disease, and two patients had abnormal liver-
associated enzymes that were attributed to excess alcohol
intake, as were their GI symptoms. The effect of cessation
of alcohol intake upon GI symptoms in these patients was
not reported. Two patients with elevated c-reactive protein
(CRP), one of who also had an elevated ESR, were found to
have IBD. These investigators also performed antigliadin
antibody (IgA and IgG) and endomysial antibody testing in
300 patients with suspected IBS and in 300 age- and gender-
matched asymptomatic controls. Positive antibody tests
were followed by upper endoscopy and distal duodenal
biopsies. Sixty-six patients (22%) with suspected IBS had
positive antibody tests, and 14 (4.67%) had histological
evidence of celiac disease compared with two (0.67%) con-
trols. The effect of a gluten-free diet upon the GI symptoms
of patients diagnosed with celiac disease was not reported in
this study.
The study by Tolliver et al. was the only one to examine
the use of FOBT in patients with suspected IBS (24). Fifteen
of 183 patients (8.2%) had a positive FOBT and subse-
quently underwent full colonoscopic examination. Four of
the 15 with positive FOBT, or 2.2% of the original cohort,
had structural abnormalities identified during colonoscopy.
None of these findings were believed to represent an alter-
native diagnosis to IBS or provide an explanation for the
patients’ IBS symptoms.
Stool Analysis for O&P
Examination of stool for O&P is commonly recommended
as a primary examination in the evaluation of patients with
suspected IBS. Two trials have evaluated the results of stool
O&P examination in this population. Hamm et al. (23)
found that 1.7% (19 of 1154) of patients with suspected IBS
had evidence of an intestinal pathogen on standard stool
O&P examination. Of these 19 subjects, eight (0.69%) were
colonized with Blastocystis hominis, a relatively common
finding of unclear clinical significance (23). Clinical out-
comes after eradication of the identified pathogens were not
reported (appropriate gold standard for this diagnosis would
be resolution of IBS symptoms after successful eradication
of infectious agent). Likewise, Tolliver et al. performed
stool O&P examinations in 170 patients with suspected IBS
and found no subjects with evidence of enteric infection
(24).
Serological Testing for the Identification of Thyroid
Dysfunction (TSH)
Two studies have evaluated the role of TSH as part of the
diagnostic evaluation of IBS. Hamm et al. performed TSH
in more than 1200 patients fulfilling the Rome I criteria and
identified 67 patients (6%) with thyroid function abnormal-
ities (23). These abnormalities were evenly distributed be-
tween hyper- and hypothyroidism. It is not clear whether
these thyroid abnormalities identified were responsible for
the patients’ IBS symptoms because there is no report of
symptom relief in response to correction of thyroid function
(again, the ultimate gold standard for hyper- or hypothy-
roidism as the etiology of IBS would be resolution of
IBS-type symptoms after treatment of the thyroid disorder).
Tolliver et al. identified one of 171 patients with suspected
IBS (0.6%) who had an abnormal TSH (24). The nature of
the thyroid dysfunction was not included in the text of the
article, nor was the impact of therapy for the thyroid abnor-
mality upon GI symptoms. These data must be considered
carefully, however, because thyroid function test abnormal-
ities are common in the general population with an expected
prevalence of 5–9% (29).
Hydrogen Breath Testing for the Identification of
Lactose Intolerance or Small Intestinal Bacterial
Overgrowth (SIBO)
The prevalence of lactose malabsorption (diagnosed via
abnormal hydrogen breath testing) is estimated to be ap-
proximately 25% in western countries and as high as 75%
worldwide (30, 31). Two trials have reported the results of
hydrogen breath testing for lactose malabsorption in patients
with suspected IBS (23, 24). One trial found that 23% (256
of 1122) of patients with suspected IBS, when administered
a 25-g lactose dose, demonstrated impaired lactose absorp-
tion (23). Response to a lactose-free diet was not reported,
so it is impossible to determine how many of these subjects
had GI symptoms caused by lactose malabsorption rather
than IBS. In another study, 186 patients with suspected IBS
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were evaluated with hydrogen breath testing (50-g dose of
lactose) (24). These investigators found a similar prevalence
of lactose malabsorption with 25.8% (48 of 186) of the
cohort having abnormal results. In a subsequent publication,
reflecting 3 yr of follow-up, these investigators demon-
strated that patients with suspected IBS diagnosed with
lactose malabsorption did not differ with regards to their GI
symptoms when compared with patients without hydrogen
breath test evidence of lactose malabsorption (32).
Pimentel et al. performed lactulose hydrogen breath test-
ing in 202 patients fulfilling the Rome I criteria referred for
evaluation of possible SIBO (28). Seventy-eight percent
(157 of 202) had breath test results that were consistent with
SIBO and were treated with a 10-day course of antibiotics.
Forty-seven of these patients (29.9%) were restudied 7–10
days after completion of the antibiotics, and SIBO eradica-
tion was achieved in 25 (53.2%). Twelve patients (48%)
with SIBO eradication did not meet the Rome I criteria
when their symptoms were reassessed, whereas only four
patients (18.2%) with persistent SIBO failed to meet the
Rome I criteria after treatment.
Imaging Studies
Francis et al. evaluated the role of abdominal ultrasound to
identify serious abdominal or pelvic pathology in 125 pa-
tients (100 women, 25 men) with suspected IBS by the
Rome I criteria (26). Twenty percent of women and 8% of
men had an abnormality of some form found on abdominal
ultrasound examination. Ten percent of women had pelvic
abnormalities, the majority of which were gynecological in
origin. The prevalence of hepatobiliary abnormalities was
similar in both women and men (10% and 8%, respectively).
Importantly, the identification of an anatomic abnormality
on ultrasound did not lead to additional therapeutic mea-
sures in any patient, nor were the authors able to correlate
any of the abnormalities identified on ultrasound to the
patients’ GI symptoms. These investigators concluded that
abdominal ultrasound in patients with the “positive diagno-
sis of IBS” via symptom-based criteria was not necessary
and may actually be counterproductive because the identi-
fication of trivial anatomic abnormalities could conceivably
lead to unnecessary patient concern and additional, more
invasive tests or procedures.
DISCUSSION
This systematic review of the trials examining the most
commonly used diagnostic tests ordered in patients with
suspected IBS identified two important points for discus-
sion. First, there are very few rigorously designed trials
examining the pretest probability and accuracy of diagnostic
tests in patients fulfilling symptom-based criteria for IBS.
Second, the available data demonstrate that patients fulfill-
ing symptom-based criteria for IBS have very low pretest
probabilities of organic GI disease, with the possible excep-
tion of celiac disease, and that most diagnostic testing in this
population may be unnecessary. In fact, the pretest proba-
bility of organic disease in patients with suspected IBS who
fulfill symptom-based criteria and do not demonstrate
“alarm” symptoms is so low that a standardized battery of
diagnostic tests to rule out organic disease may not be
necessary.
Based upon the available data, the pretest probability of
identifying organic GI disease responsible for IBS symp-
toms through colonic visualization with flexible sigmoidos-
copy, barium enema, or colonoscopy is less than 1%. Most
identified colonic abnormalities are asymptomatic (e.g., pol-
yps, diverticulosis) (33). The performance of rectal biopsies
also failed to generate alternative diagnoses in the one
prospective study that examined its use (25). Abdominal
imaging via ultrasound examination also failed to detect any
serious GI pathology or result in a change of the diagnosis
or management of IBS in the one study that evaluated its use
(26).
Data regarding the use of standard laboratory tests such as
CBC, serum chemistries, TSH, ESR/CRP, stool O&P, and
FOBT are similarly lacking. In the two trials that included
CBC as part of the evaluation of patients with suspected
IBS, only one patient was found to have an organic GI
disease as a consequence of performing this test (24, 27).
Both studies reported that performance of routine serum
chemistries was similarly disappointing. Performance of
TSH and stool examinations for O&P and occult blood also
failed to identify a significantly greater degree of organic GI
disease in patients with suspected IBS compared with his-
torical prevalence rates in the general population.
One study reported a significantly higher pretest proba-
bility for celiac disease in patients with suspected IBS
compared with controls and historical prevalence rates (27,
34). Unfortunately, response to a gluten-free diet was not
reported in this study. In an ideal study, patients diagnosed
with celiac disease would have been treated with a gluten-
free diet and followed to determine if this intervention was
associated with resolution of their IBS symptoms. Recently,
Wahnschaffe et al. examined the prevalence of celiac dis-
ease in a group of patients with suspected IBS and found
that human leukocyte antigen subtype DQ2 genotype, duo-
denal biopsies with increased intraepithelial lymphocytes,
and duodenal aspirates with elevated IgA antigliadin anti-
bodies all supported the diagnosis of celiac disease in 23–
35% of these patients (35). This study was not included in
our formal systematic review, as it did not define IBS
patients using formal symptom-based criteria. Surprisingly,
none of the patients with suspected IBS diagnosed with
celiac disease in this study had elevated serum antigliadin
antibodies or tissue transglutaminase antibodies. A gluten-
free diet was associated with improved GI symptoms in a
subset of patients with suspected IBS diagnosed with celiac
disease, but only 26 patients were studied. Therefore, this
study suggests that serum antibody testing for celiac disease
has a highly variable sensitivity, which appears to be at least
in part related to the severity of intestinal injury (36, 37).
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Nevertheless, the identification of celiac disease is quite
attractive given the availability of effective therapy and the
ability of this therapy to prevent significant long-term mor-
bidity. Thus, diagnostic testing for celiac disease may be
considered routinely in patients who fulfill symptom-based
criteria for IBS.
There is also some evidence that SIBO may play a role in
a subset of those patients with symptoms attributed to IBS.
However, well-designed clinical trials with appropriate
treatment and adequate follow-up are necessary before
adopting this association as part of the clinical mainstream.
The results of the one report included in this review must be
interpreted with caution because of the use of a suboptimal
gold standard for SIBO, open label diagnosis and treatment,
and the low rate of follow-up testing and documentation of
treatment effect in only a small number of patients (28).
Such evaluation was carried out in only 30% (47 of 157) of
the original study cohort. Follow-up was also limited with a
one-time reassessment of GI symptoms within 7–10 days
after antibiotic treatment. Long-term, repeated reassessment
of symptom-based IBS criteria and SIBO status in a larger
number of patients would help strengthen the possible link
between SIBO and IBS.
The community adherence to the currently recommended
diagnostic evaluation of IBS is not known. However, it is
known that additional diagnostic testing to exclude organic
GI disease does contribute to the significant economic bur-
den associated with this condition (3, 4). At first glance,
based upon the results of this systematic review, the low
pretest probability of organic GI disease among patients
who meet symptom-based criteria for IBS argues against an
exhaustive diagnostic evaluation for organic GI disease.
However, several points regarding this conclusion merit
discussion. A diagnostic evaluation is indicated if the patient
has “alarm” symptoms, such as age 50 yr, weight loss,
gross hematochezia, or systemic signs of infection or colitis.
Additionally, the true value, for both patients with suspected
IBS and their physicians, of a negative diagnostic evaluation
might derive from the reassurance that they do not have an
organic GI disease. Such reassurance from a negative eval-
uation may have beneficial effects upon symptom response
regardless of any therapeutic intervention undertaken by the
health care provider. Unfortunately, such an intangible and
subjective outcome is difficult to measure and may be
equally achievable through a well-developed patient-physi-
cian relationship. Much of the data regarding the diagnostic
evaluation of patients with suspected IBS originate from
secondary and tertiary referral centers, and the apparent
pretest probability of organic GI disease in patients from
these referral sites may be misrepresented as a result of this
potential bias. Lastly, the average age of the patients in all
of the studies reviewed ranged from 39 to 56 yr, so the
pretest probability of organic diseases that are more preva-
lent with advanced age, such as colon cancer, would be
expected to be lower in these cohorts than historical con-
trols.
Future research in this area is needed and should address
the following points. First, what is the overall rate of com-
pliance with published clinical practice guidelines for the
diagnosis of IBS? Second, given the lack of available data,
there is a need for additional large, well-designed prospec-
tive trials (38) with adequate follow-up to examine the yield
and accuracy of commonly used diagnostic tests obtained as
part of the evaluation of IBS. If organic GI disease is
diagnosed, then patients should be followed, after appropri-
ate treatment, with periodic reassessment of their IBS symp-
toms to determine if treatment of the organic GI disease
significantly impacts upon their clinical course. The findings
of this systematic review have additional implications for
the design of future IBS trials. Our results suggest that
performing rigorous, invasive, and expensive diagnostic
evaluations in potential study participants who clearly fulfill
symptom-based criteria for IBS may not be necessary.
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